文献速递血液净化与透析慢性肾脏病

应用通用恶病质定义识别血液透析患者恶病质的纵向初步研究

Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

本研究为英国两家医院血液透析单元的纵向研究,纳入106例成年慢性HD患者,采用通用恶病质定义(体重下降>5%持续>6个月或BMI<20 kg/m2,且具备≥3项临床特征)识别恶病质,随访12个月。结论认为恶病质严重但常被低估,需更广泛研究建立晚期CKD恶病质表型。

要点

  • 通用恶病质定义可用于血液透析患者识别,基线106例中17例为恶病质。
  • 随访12个月,FAACT和尿素下降率可统计学区分恶病质与非恶病质患者(P=0.001)。
  • 恶病质患者体重、BMI、MUAMC、HGS、CRP、ERI和FACIT等指标趋于恶化。

核心结论

  • 恶病质在血液透析患者中是严重但常被低估的问题,本研究首次将通用恶病质定义应用于代表性HD样本。
  • 需进一步更广泛研究以建立晚期CKD恶病质表型。

研究设计与样本

  • 纵向研究,纳入英国两家医院血液透析单元的106例成年慢性HD患者(女30例,男76例),平均年龄67.6岁(SD 13.18),透析龄4.92年(SD 6.12)。
  • 基线分析采用独立t检验、χ2检验报告患病率,纵向分析采用重复测量分析。

主要发现

  • 基线17例被识别为恶病质,符合体重下降(如>5%持续>6个月)或BMI<20 kg/m2且具备≥3项恶病质临床特征。
  • FAACT和尿素下降率可统计学区分恶病质患者(P=0.001)。
  • 体重、BMI、MUAMC、HGS、CRP、ERI和FACIT等指标在恶病质患者中趋于恶化。

关键数值与推荐

  • 恶病质识别标准:体重下降>5%持续>6个月或BMI<20 kg/m2,且具备≥3项恶病质临床特征。
  • 评估指标包括BMI、MUAMC、HGS、FACIT、FAACT、CRP、血清白蛋白、血红蛋白和ERI。

临床怎么用

  • 对血液透析患者可采用通用恶病质定义(体重下降>5%持续>6个月或BMI<20 kg/m2且≥3项临床特征)进行筛查。
  • FAACT和尿素下降率有助于区分恶病质患者,可结合体重、BMI、MUAMC、HGS、CRP、ERI和FACIT等指标动态监测。

局限性

  • 研究仅纳入英国两家医院HD单元患者,代表性可能受限。
  • 需更广泛研究建立晚期CKD恶病质表型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research indicates that cachexia is common among persons with chronic illnesses and is associated with increased morbidity and mortality. However, there continues to be an absence of a uniformed disease-specific definition for cachexia in chronic kidney disease (CKD) patient populations. OBJECTIVE: The primary objective was to identify cachexia in patients receiving haemodialysis (HD) using a generic definition and then follow up on these patients for 12 months. METHOD: This was a longitudinal study of adult chronic HD patients attending two hospital HD units in the UK. Multiple measures relevant to cachexia, including body mass index (BMI), muscle mass [mid-upper arm muscle circumference (MUAMC)], handgrip strength (HGS), fatigue [Functional Assessment of Chronic Illness Therapy (FACIT)], appetite [Functional Assessment of Anorexia/Cachexia Therapy (FAACT)] and biomarkers [C-reactive protein (CRP), serum albumin, haemoglobin and erythropoietin resistance index (ERI)] were recorded. Baseline analysis included group differences analysed using an independent t-test, dichotomized values using the χ2 test and prevalence were reported using the Statistical Package for the Social Sciences 24 (IBM, Armonk, NY, USA). Longitudinal analysis was conducted using repeated measures analysis. RESULTS: A total of 106 patients (30 females and 76 males) were recruited with a mean age of 67.6 years [standard deviation (SD) 13.18] and dialysis vintage of 4.92 years (SD 6.12). At baseline, 17 patients were identified as cachectic, having had reported weight loss (e.g. >5% for >6 months) or BMI <20 kg/m2 and three or more clinical characteristics of cachexia. Seventy patients were available for analysis at 12 months (11 cachectic versus 59 not cachectic). FAACT and urea reduction ratio statistically distinguished cachectic patients (P = 0.001). However, measures of weight, BMI, MUAMC, HGS, CRP, ERI and FACIT tended to worsen in cachectic patients. CONCLUSION: Globally, cachexia is a severe but frequently underrecognized problem. This is the first study to apply the defined characteristics of cachexia to a representative sample of patients receiving HD. Further, more extensive studies are required to establish a phenotype of cachexia in advanced CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. McKeaveney C, Slee A, Adamson G, et al. Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study. Nephrol Dial Transplant. 2021. PMID: 33150449. doi:10.1093/ndt/gfaa174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。